MedTrace Logo

Digital Health Program With Participants Using an Autoinjector

NCT06112184 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-05-25

No results posted yet for this study

Summary

This is a prospective, single-arm, feasibility study. Up to thirty (30) participants meeting study eligibility criteria will use the SK-M11/3A1 digital health program for 12 weeks. The program will be delivered via the Sidekick mobile application (app).

The study objective is to evaluate the performance and safety of the SK-M11/3A1 digital health program when added to routine medical treatment of patients with Immune-Mediated Inflammatory Disease (IMID). All participants are using a prescribed medication for regular subcutaneous injection provided in a prefilled autoinjector.

Conditions

  • Immune-Mediated Inflammatory Disease

Interventions

OTHER

SK-M11/3A1 Digital health program

Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)

Sponsors & Collaborators

  • Sidekick Health

    lead INDUSTRY

Principal Investigators

  • Bárður L Sigurgeirsson, MD, PhD · Húðlæknastöðin

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-10
Primary Completion
2024-10-01
Completion
2024-10-01

Countries

  • Iceland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06112184 on ClinicalTrials.gov